key: cord-0900243-lzbpipqz
authors: Hon, Kam L.; Leung, Karen K. Y.
title: From influenza to COVID‐19 vaccinations: Counselling anxious parents about deaths following influenza immunizations in Korea
date: 2021-03-25
journal: Pediatr Pulmonol
DOI: 10.1002/ppul.25260
sha: d75b95a8a460ffc146219af4cc20c66e29dfacb0
doc_id: 900243
cord_uid: lzbpipqz

nan

To the Editor, Hong Kong citizens and anxious parents are astonished by the news that over 80 deaths have been reported following influenza immunizations in Korea, while some adverse events were also brought to the public's attention in Taiwan. 1 In Korea, the vaccine providers are believed to include domestic firms such as GC Pharma, SK Bioscience, Korea Vaccine, and Boryung Biopharma Co Ltd, a unit of Boryung Pharm Co Ltd, along with Sanofi which is headquartered in France. 2 The reports raised yet further concerns amongst the general public after the Singapore Ministry of Health advised temporary cessation for the use of two vaccines, one of which is used in Hong Kong. This episode could become an international crisis as the annual winter surge of influenza is just around the corner and raise serious public concerns. We analyze and search the literature to provide some facts which can help address these questions and further discuss the role of vaccination in combating influenza and COVID-19 from a public health perspective.

Influenza vaccines are one of the most well-studied pharmaceutical products in use with a very good safety profile established over many decades. Mortality associated with influenza vaccines have not been reported in recent years, and plausible theoretical explanations of death following influenza vaccination could potentially include anaphylaxis, Guillain-Barré syndrome, fallrelated injuries associated with syncope, postvaccinal encephalitis, and myocarditis. 3 The Korean Disease Control and Prevention (KDCP) agency has thoroughly examined the reported deaths and concluded that causality with influenza vaccination cannot be established. According to the KDCP, more than 11.5 million South Koreans received their influenza vaccination this year, which is The vaccine comes in either inactive or weakened viral forms. 7 The live, attenuated vaccine is generally not recommended in pregnant women, children less than 2 years old, adults older than 50, or immunocompromised people. 7 They can be injected intramuscular, sprayed into the nose, or injected intradermal. 7 The inactivated flu vaccine is widely used and is largely produced using egg-based techniques. They are nonetheless still recommended for people with egg allergies, as studies examining the safety of influenza vaccines in people with severe egg allergies found that anaphylaxis is very rare, occurring in 1.3 cases per million doses given. 11 A study of nearly 800 children with egg allergies, including over 250 with previous anaphylactic reactions, resulted in zero systemic allergic reactions when given the live attenuated flu vaccine. 12,13 However, influenza vaccines are not recommended in those who have had a severe allergy to previous versions of the vaccine itself. 7, 11 Physicians are obligated to counseling anxious parents that influenza vaccines are generally safe. 7 Minor side effects that are relatively common include soreness, redness, temporary muscle pain, tiredness, swelling around the point of injection, headache, fever, nausea, or fatigue. [4] [5] [6] [7] 14 Side effects of a nasal spray vaccine may include runny nose, wheezing, sore throat, cough, or vomiting. 14 Fever occurs in five to ten percent of vaccinated children. 7 Influenza vaccine has been linked to an increase in Guillain-Barré syndrome among older people at a rate of about one case per million doses. 7 However, most studies on modern influenza vaccines have seen no link with Guillain-Barré syndrome. 15, 16 A separate review estimated an incidence of about one case of Guillain-Barré syndrome per million vaccinations. 17 Infection Isolation Rooms (AIIR) even for the "asymptomatic" or mild disease are all ideal from a medical perspective, but clearly not practical for this transmissible respiratory disease with and R 0 of 2-3 and the majority being asymptomatic or mildly symptomatic. Just like vaccination is not the ultimate solution for flu, vaccination alone will not be sufficient to bring an end to the COVID-19 pandemic. Furthermore, a large UK population surveillance study found that the proportion of people who tested positive for COVID-19 antibodies in the study population fell by 26.5% over 3 months. 20 Although it is unclear how the level of antibodies correlates with the effective level of immunity, lasting immunity from vaccination and herd immunity may be difficult to achieve for COVID-19. In conjunction with vaccination, a combination of low cost rapid COVID-19 testing which can be widely deployed, vigilant contact tracing, and isolation might be exit strategies that could bring the COVID-19 pandemic under control, allowing the resumption of "normal" social and economical activities.

Until the development and availability of novel vaccines and therapeutics options with good efficacy and safety profile, we will need to learn from our vast experience in the management of influenza epidemics and other past pandemics in the history of mankind. With the alertness in personal hygiene and mass mask-wearing behavior due to SARS, the incidence of influenza and respiratory viral diseases was much reduced in 2003. 21 Out of all public health policies available today, influenza vaccination is a low-hanging fruit and should be actively encouraged. Given the relatively low influenza vaccination rate in Hong Kong (Table 1) , healthcare professionals should continue to promote the importance of these safe and reliable interventions, and dismiss the misinformation and fallacies in the general public. Vaccine hesitancy, also known as anti-vaccination or anti-vax, is a reluctance or refusal to be vaccinated or to have one's children 

Press Release: Influenza Vaccinations for the

00:00)

South Korea Presses on with Flu Vaccination Programme amid Concerns about Deaths

Deaths following vaccination: what does the evidence show? Vaccine

Results of immunization by means of active virus of human influenza

A decade in review: a systematic review of universal influenza vaccines in clinical trials during the 2010 decade

The Search for the Ideal Influenza Vaccine

Vaccines Against Influenza WHO Position Paper

Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses

-19 Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination

Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study

Centers for Disease Control and Prevention. Misconceptions about Seasonal Flu and Flu Vaccines

Guillain-Barré syndrome, influenza, and influenza vaccination: the epidemiologic evidence

Vaccines and Guillain-Barré syndrome

Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population-and registry-based cohort study with over 2 years of follow-up

Largest COVID-19 Antibody Testing Programme Publishes Findings on Antibody Response Over Time

Severe acute respiratory symptoms and suspected SARS again 2020

Details of Vaccination Subsidy Scheme -Seasonal Influenza Vaccination

Statistics on 2020/21 Vaccination Programmes/Schemes